Clinical significance of microtubule-associated protein 1 light chain 3 and mammalian target of rapamycin expression in oral leukoplakia in smokers and never-smokers

doi:10.7518/hxkq.2019.01.004

Abstract

Abstract:

Objective This study aimed to investigate the expression patterns and relationship of microtubule-associated protein 1 light chain 3 (LC3B) and mammalian target of rapamycin (mTOR) in oral leukoplakia (OLK) in smokers and never-smokers. This work also analyzed the relationship between smoking and the carcinogenic potential of OLK. Methods Immu-nohistochemistry was used to detect the expression of LC3B and mTOR in 120 patients with OLK. Clinical data from 120 smokers and never-smokers with OLK were analyzed. Subsequently, the relationships among LC3B and mTOR expression, clinical factors, and smoking were analyzed. Results Smoking and nonsmoking patients with OLK differed in terms of gender, age, lesion location, pathological typing, and carcinogenic situation. The positive rate of LC3B in never-smokers was higher than that in smokers. Whereas the positive rate of mTOR in smokers was higher than that in the corresponding never-smokers, and the differences were statistically significant (P<0.05). Smoking was positively correlated with the positive rate of mTOR (P<0.05), and had no significant correlation with LC3B expression. The positive rates of LC3B and mTOR were negatively correlated with the intensity of smoking (P<0.05). Conclusion The effect of smoking habits on OLK may be linked to the expression of proteins that are directly associated with autophagy.

Key words: microtubule-associated protein 1 light chain 3, mammalian target of rapamycin, smoking, oral cavity, leukoplakia

CLC Number:

R781.5

Xiaolin Dong,Zhiwen Liu. Clinical significance of microtubule-associated protein 1 light chain 3 and mammalian target of rapamycin expression in oral leukoplakia in smokers and never-smokers[J]. West China Journal of Stomatology, 2019, 37(1): 19-24.

Figures/Tables 6

Tab 1

Fig 1.

Tab 2

Tab 3

Fig 2.

Fig 3.

References 16

[1]	Seoane J, Alvarez-Novoa P, Gomez I , et al. Early oral cancer diagnosis: the Aarhus statement perspective. A systematic review and meta-analysis[J]. Head Neck, 2016,38(Suppl 1):E2182-E2189. doi: 10.1002/hed.24050 URL
[2]	Krishna Rao SV, Mejia G, Roberts-Thomson K , et al. Epide-miology of oral cancer in Asia in the past decade: an update (2000—2012)[J]. Asian Pac J Cancer Prev, 2013,14(10):5567-5577. doi: 10.7314/APJCP.2013.14.10.5567 URL
[3]	Petti S . Pooled estimate of world leukoplakia prevalence: a systematic review[J]. Oral Oncol, 2003,39(8):770-780. doi: 10.1016/S1368-8375(03)00102-7 URL
[4]	Liu W, Wang YF, Zhou HW , et al. Malignant transforma-tion of oral leukoplakia: a retrospective cohort study of 218 Chinese patients[J]. BMC Cancer, 2010,10:685. doi: 10.1186/1471-2407-10-685 URL
[5]	Abidullah M, Kiran G, Gaddikeri K , et al. Leuloplakia—review of a potentially malignant disorder[J]. J Clin Diagn Res, 2014, 8(8): ZE01-ZE04.
[6]	Lima JS , Pinto Ddos S Jr, Sousa SO, et al. Oral leukoplakia manifests differently in smokers and non-smokers[J]. Braz Oral Res, 2012,26(6):543-549. doi: 10.1590/S1806-83242012005000024 URL
[7]	Amaravadi RK, Lippincott-Schwartz J, Yin XM , et al. Prin-ciples and current strategies for targeting autophagy for can-cer treatment[J]. Clin Cancer Res, 2011,17(4):654-666. doi: 10.1158/1078-0432.CCR-10-2634 URL
[8]	Lai K, Killingsworth M, Yong J , et al. Specific localization of LC3B in autophagosome: a correlative labelling study with nanoparticle in oral squamous cell carcinoma[J]. Exp Mol Pathol, 2017,102(3):422-427. doi: 10.1016/j.yexmp.2017.05.007 URL
[9]	Ladoire S, Penault-Llorca F, Senovilla L , et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer[J]. Autophagy, 2015,11(10):1878-1890. doi: 10.1080/15548627.2015.1082022 URL
[10]	Granero Fernandez M, Lopez-Jornet P . Association between smoking, glycaemia, blood lipoproteins and risk of oral leu-koplakia[J]. Aust Dent J, 2017,62(1):47-51. doi: 10.1111/adj.2017.62.issue-1 URL
[11]	van der Waal I . Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management[J]. Oral Oncology, 2010,46(6):423-425. doi: 10.1016/j.oraloncology.2010.02.016 URL
[12]	Roy B, Pattanaik AK, Das J , et al. Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced auto-phagy in HeLa cells[J]. Chem Biol Interact, 2014,210:96-102. doi: 10.1016/j.cbi.2014.01.003 URL
[13]	Zou Y, Ge MG, Wang XM . Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo[J]. Biochem Biophys Res Commun, 2017,490(2):385-392. doi: 10.1016/j.bbrc.2017.06.052 URL
[14]	董小琳, 柳志文 . 口腔白斑和口腔鳞状细胞癌中微管相关蛋白1轻链3和雷帕霉素靶蛋白的表达及临床意义[J]. 华西口腔医学杂志, 2018,36(6):613-618.
	Dong XL, Liu ZW . Clinical importance of microtubule-associated protein 1 light chain 3 and mammalian target of rapamycin expression in oral leukoplakia and oral squamous cell carcinoma[J]. West Chin J Stomatol, 2018,36(6):613-618.
[15]	关晓兵, 孙正, 王建滨 . 口腔白斑癌变与吸烟关系的初步探讨[J]. 北京口腔医学, 2001,9(3):123-124.
	Guan XB, Sun Z, Wang JB . Preliminary study on the rela-tionship between smoking and malignant transformation of oral leukoplakia[J]. Beijing J Stomatol, 2001,9(3):123-124.
[16]	Lima JS, Correa L, Klingbeil MF , et al. C-Jun, pc-Jun, and p27 are differently expressed in oral leukoplakias in smokers and never-smokers[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016,121(1):73-80. doi: 10.1016/j.oooo.2015.09.003 URL

临床因素		吸烟组		P值	不吸烟组		P值
		OLK单纯增生	OLK异常增生		OLK单纯增生	OLK异常增生
		（n=19）	（n=78）		（n=11）	（n=12）
吸烟数量/（支·天^-1）*		22（4~44）	26（9~46）
烟龄/年*		28（11~54）	46（19~59）
年龄/岁*		48（26~71）	56（44~80）		52（39~84）	66（33~86）
<50		5（26.3）	16（20.5）	0.023^F	8（72.7）	9（75.0）	0.000^b
≥50		14（73.7）	62（79.5）		3（27.3）	3（25.0）
性别	男	17（89.5）	73（93.6）	0.001^F	3（27.3）	7（58.3）	0.002^b
	女	2（10.5）	5（6.4）		8（72.7）	5（41.7）
发病部位	舌及口底	7（36.8）	69（88.5）	0.026^F	9（81.8）	7（58.3）	0.024^b
	其他	12（63.2）	9（11.5）		2（18.2）	5（41.7）
病理类型	轻度异常		21（26.9）			9（75.0）	0.003^b
	中、重度异常		57（73.1）			3（25.0）
恶变与否	是	13（68.4）	56（71.8）	0.021^F	2（18.2）	4（33.3）	0.009^b
	否	6（31.6）	22（28.2）		9（81.8）	8（66.7）

阳性表达	吸烟（n/%）		不吸烟（n/%）		P值
阳性表达	OLK单纯增生（n=19）	OLK异常增生（n=78）	OLK单纯增生（n=11）	OLK异常增生（n=12）	P值
LC3B	15/78.9	45/57.7	10/90.9	9/75.0	0.024
mTOR	7/36.8	44/56.4	4/36.4	3/25.0	0.026

阳性表达	吸烟（n/%）		不吸烟（n/%）
阳性表达	OLK轻度异常增生（n=21）	OLK中、重度异常增生（n=57）	OLK轻度异常增生（n=9）	OLK中、重度异常增生（n=3）
LC3B	14/66.7	30/52.6	8/88.9	2/66.7
mTOR	9/42.9	34/59.6	3/33.3	1/33.3